ArticleFrontiers in pharmacology2025
Antidepressant use in the Canary Islands (Spain): a retrospective study of provincial, island and municipal trends and associated factors.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The presence of a diagnosis by a general practitioner is a major reason for the use of antidepressant (ADs). However, the simultaneous analysis of several and interrelated socioeconomic and demographic factors could provide a picture of the distribution of AD use in a given population across diverse geographical regions and socioeconomic backgrounds. The aim of the present study was to provide a picture of the trends in the consumption of ADs at the provincial, island and municipal levels for the period 2016-2021 in the Canary Islands (Spain), as an example of a geographically isolated area. To this end, several factors were analyzed, such as living in a rural or urban area, the population over 65 years of age, the population density or the socioeconomic status. Methods: Data were extracted from the community pharmacy wholesaler at the population level. A model with two nested fixed factors and a co-variable were used to analyze the trends in the use of ADs and the factors associated. Dispensation ADs use was measured as defined daily doses (DDD) per 1000 inhabitant per day. This provided total overall dispensation of AD and its rate of change for each island, as well as differences in dispensation at the island and municipal level. Results: Over the study period, prescription rates increased steadily at all population levels, although the level of dispensing and the rate of variation varied between island and municipalities but no between provinces. The data on the use of ADs at the level of the province and islands are more accurate because they include the entire population that is resident in that zone. At the municipal level, there is a bias, but it is difficult to quantify. The prescription patterns at municipal level were similar to those observed at island level, although with small variations in the dispensation level. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly used, followed by "other ADs," whereas the use of tricyclic ADs remained stable. 1n addition, all AD drugs are equally available regardless of the geographical area of residence or socio-economic status although the type of AD and ranking varied slightly between islands due to the differences in general medical practice. Conclusion: The observed differences in ADs use between rural and urban areas cannot be attributed to the factors of urbanization, population age, population density and socioeconomic status. However, the medical practices, the social and cultural traditions of each island, may provide insights into the underlying reasons for this variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.